Results 251 to 260 of about 268,746 (338)
Osteosarcoma is the most common primary bone tumor with limited treatment options and a terrible prognosis. This review provides a comprehensive summary of the recent development of osteoimmunomodulatory implants for post‐operative osteosarcoma treatment, of which the potential utility in evoking durable anti‐osteosarcoma immunity and accelerating bone
Yilong Dong +6 more
wiley +1 more source
Prevalence and Characteristics of Sexual Dysfunction in Patients Treated with Immune Checkpoint Inhibitors. [PDF]
Aktepe B +7 more
europepmc +1 more source
Chemotherapy‐induced efferocytosis drives ovarian cancer stem cell enrichment. By engulfing apoptotic cancer cells, macrophages upregulate ODC1 and produce putrescine, which elevates osteopontin (OPN) expression. Secreted OPN then activates the CD44 receptor on cancer cells, promoting stemness and chemoresistance.
Wenhan Li +19 more
wiley +1 more source
Progress of immune checkpoint inhibitors in gastric cancer. [PDF]
Wan JY, Zhang D, Wu XH, Yang H, Dong C.
europepmc +1 more source
METTL5 Enables Immune Evasion of Liver Cancer via Chemokine mRNA Translation Regulation
METTL5 reshapes the tumor immune microenvironment through ribosome 18S rRNA m6A modification to regulate the translation of chemokine mRNA. Targeting METTL5‐mediated immunosuppression unleashes anti‐tumor immunity and improves the efficacy of anti‐PD‐1 therapy.
Shuang Li +19 more
wiley +1 more source
Albumin-globulin ratio is a predictive biomarker of antitumour effect of immune checkpoint inhibitors in cancer patients. [PDF]
He K, Xu F, Xiang L, Luo Y.
europepmc +1 more source
A Rationally Engineered Spleen‐Tropic One‐Component Lipid‐mRNA Complex (OncoLRC) for Cancer Vaccines
OncoLRC, a one‐component lipid‐mRNA complex, enables efficient spleen‐targeted delivery at an exceptionally low lipid‐to‐mRNA mass ratio (1.5:1), robustly activates immune responses, inhibits tumor growth, and synergizes with checkpoint blockade, presenting a next‐generation platform for mRNA vaccines.
Qimeng Yin +4 more
wiley +1 more source
Unraveling resistance to immune checkpoint inhibitors in HNSCC: from mechanisms to combination therapies. [PDF]
Zhao W, Luo Q, Yuan B, Duan H, Jiang S.
europepmc +1 more source
Tumor evolution in lung adenocarcinoma is shaped by genetic alterations and spatial immune dynamics. By integrating whole‐exome sequencing, imaging mass cytometry, and spatial transcriptomics across two mouse models, this study reveals how mutational burden, immune infiltration, and cell–state interactions evolve during early and late carcinogenesis ...
Bo Zhu +34 more
wiley +1 more source

